Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility

被引:78
作者
Bolan, CD
Childs, RW
Procter, JL
Barrett, AJ
Leitman, SF
机构
[1] NHLBI, Dept Transfus Med, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA
[2] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
关键词
ABO incompatibility; haemolysis; PBSC; stem cell transplantation;
D O I
10.1046/j.1365-2141.2001.02587.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune haemolysis as a result of minor ABO incompatibility is an underappreciated complication of haematopoietic transplantation. The increased lymphoid content of peripheral blood stem cell (PBSC) transplants may increase the incidence and severity of this event. We observed massive immune haemolysis in 3 out of 10 consecutive patients undergoing HLA-identical, related-donor PBSC transplants with minor ABO incompatibility. Non-ablative conditioning had been given in 9 of these 10 cases, including two with haemolysis. Cyclosporin alone was used as prophylaxis against graft-vs.-host disease (GVHD). Catastrophic haemolysis of 78% of the circulating red cell mass led to anoxic death in the first case seen, but severe consequences were avoided by early, vigorous donor-compatible red cell transfusions in the subsequent two cases, Haemolysis began 7-11 d after PBSC infusion and all patients with haemolysis had a positive direct antiglobulin test (DAT), with eluate reactivity against the relevant recipient antigen. However, neither the intensity of the DAT the donor isohaemagglutinin titre, nor other factors could reliably be used to predict the occurrence of haemolysis. Our data indicate that haemolysis may be frequent and severe after transplantation of minor ABO-incompatible PBSCs when utilizing cyclosporin alone to prevent GVHD. Meticulous clinical monitoring and early, vigorous donor-compatible red cell transfusions should be practiced in all instances.
引用
收藏
页码:787 / 795
页数:9
相关论文
共 35 条
[1]   Choosing the source of stem cells for allogeneic transplantation: No longer a peripheral issue [J].
Appelbaum, FR .
BLOOD, 1999, 94 (02) :381-383
[2]  
ATKINSON K, 1986, BRIT J HAEMATOL, V63, P231
[3]   RED-CELL BOUND ANTI-A IS MORE EFFICIENT THAN ANTI-B IN COMPETITION FOR FLUID-PHASE COMPLEMENT [J].
BAKACS, T ;
TUSNADY, G ;
VEGH, Z ;
MERRY, AH ;
KERTESZ, Z ;
KLEIN, E .
IMMUNOLOGY LETTERS, 1993, 35 (03) :213-218
[4]   T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect [J].
Barrett, AJ ;
Mavroudis, D ;
Tisdale, J ;
Molldrem, J ;
Clave, E ;
Dunbar, C ;
Cottler-Fox, M ;
Phang, S ;
Carter, C ;
Okunnieff, P ;
Young, NS ;
Read, EJ .
BONE MARROW TRANSPLANTATION, 1998, 21 (06) :543-551
[5]  
Bensinger W, 1999, BLOOD, V94, p368A
[6]   Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis [J].
Bornhauser, M ;
Ordemann, R ;
Paaz, U ;
Schuler, U ;
Kompf, J ;
Holig, K ;
Ehninger, G .
BONE MARROW TRANSPLANTATION, 1997, 19 (03) :295-297
[7]   Mini-allografts: ongoing trials in humans [J].
Carella, AM ;
Champlin, R ;
Slavin, S ;
McSweeney, P ;
Storb, R .
BONE MARROW TRANSPLANTATION, 2000, 25 (04) :345-350
[8]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[9]   Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect [J].
Childs, RW ;
Clave, E ;
Tisdale, J ;
Plante, M ;
Hensel, N ;
Barrett, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2044-2049
[10]  
GAJEWSKI JL, 1992, BLOOD, V79, P3076